Kojin Therapeutics
Kojin Therapeutics is a biotechnology company developing small-molecule modulators of ferroptosis. The company combines computational chemistry, structural biology, chemical biology, target-informed screening, and mechanism-driven pharmacology to discover and advance preclinical programs (including inhibitors of glutamate-cysteine ligase) for oncology and other diseases where ferroptosis is implicated.
Industries
Nr. of Employees
small (1-50)
Patents
Products
Preclinical ferroptosis-modulator programs (GCL inhibitors)
Discovery and preclinical development of small-molecule inhibitors of glutamate-cysteine ligase and additional ferroptosis-pathway targets intended to treat ferroptosis-sensitive cancers and other diseases.
Integrated small-molecule discovery platform
Platform combining computational chemistry, structural biology, chemical biology, and target-informed screening to discover and advance small-molecule therapeutics.
Preclinical ferroptosis-modulator programs (GCL inhibitors)
Discovery and preclinical development of small-molecule inhibitors of glutamate-cysteine ligase and additional ferroptosis-pathway targets intended to treat ferroptosis-sensitive cancers and other diseases.
Integrated small-molecule discovery platform
Platform combining computational chemistry, structural biology, chemical biology, and target-informed screening to discover and advance small-molecule therapeutics.
Expertise Areas
- Ferroptosis biology and cell-state targeting
- Small-molecule drug discovery
- Medicinal chemistry and high-throughput synthesis
- Computational chemistry and structural biology
Key Technologies
- Computational chemistry
- Structure-based drug design
- Chemical biology
- Target-informed screening
News & Updates
Press release announcing appointment of Harvey J. Berger, M.D. as Chairman, President and CEO.
Press release announcing appointment of Harvey J. Berger, M.D. as Chairman, President and CEO.